RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication
Artículo científico (JournalArticle)
Targeted killing of prostate cancer cells using antibody¿drug conjugated carbon nanohorns.
[EN] The ability of carbon nanohorns (CNHs) to cross biological barriers makes them potential carriers for
delivery purposes. In this work, we report the design of a new selective antibody¿drug nanosystem
based on CNHs for the treatment of prostate cancer (PCa). In particular, cisplatin in a prodrug form and
the monoclonal antibody (Ab) D2B, selective for PSMA+ cancer cells, have been attached to CNHs due
to the current application of this antigen in PCa therapy. The hybrids Ab¿CNHs, cisplatin¿CNHs and
functionalised-CNHs have also been synthesized to be used as control systems. The efficacy and
specificity of the D2B¿cisplatin¿CNH conjugate to selectively target and kill PSMA+ prostate cancer cells
have been demonstrated in comparison with other derivatives. The developed strategy to functionalise
CNHs is fascinating because it can allow the fine tuning of both drug and Ab molecules attached to
the nanostructure in order to modulate the activity of the nanosystem. Finally, the herein described
methodology can be used for the incorporation of almost any drugs or Abs in the platforms in order to
create new targeted drugs for the treatment of different diseases., G. F. gratefully acknowledges Fondazione Cariverona, Verona Nanomedicine Initiative and Italian Minister of Health RF-2010-2305526 for supporting this work. M. M. thanks the University of Padova (P-DiSC #04BIRD2016-UNIPD). This work was also supported by the Spanish Ministry of Economy and Competitiveness MINECO (projects CTQ2014-53600-R and CTQ2016-76721-R), by the EU Graphene-based disruptive technologies, Flagship project (no. 696656). M. P., as the recipient of the AXA Chair, is grateful to the AXA Research Fund for financial support. M. P. was also supported by Diputacion Foral de Gipuzkoa program Red (101/16).